Compare AstraZeneca plc (AZN) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs SOLAI Limited — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: AstraZeneca plc is far larger — about 14867.6× SOLAI Limited's market cap, and AstraZeneca plc pays a 2.01% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| AZN | SLAI | |
|---|---|---|
Market Cap | $248.14B | $16.69M |
Sector | Health | Technology |
52-Week High | $209.48 | $26.74 |
52-Week Low | $147.06 | $2.74 |
Enterprise Value | $275.41B | $16.33M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal, but the company faces severe financial distress with negative gross and net income margins, and a net loss of $33.88 million in 2025. A reverse stock split was executed on July 6, 2026, and the NYSE has commenced delisting proceedings, creating significant uncertainty.
The outlook is highly speculative. The acquisition of a stake in NEURALAND and the launch of Solode Neo represent potential growth avenues, but the delisting risk and persistent losses overshadow any near-term upside. Investors face substantial risk of capital loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
